NCT03611816 Biological Bank for Atrial Fibrillation and Stroke
| NCT ID | NCT03611816 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2018-04-23 |
| Primary Completion | 2033-04-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2018-04-23 with a primary completion date of 2033-04-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.
Eligibility Criteria
Group 1a * Inclusion Criteria : \- AF history * Exclusion Criteria : * No AF history * patient who didn't signed consent Group 1b * Inclusion Criteria : * AF history * Scheduled electrophysiological exploration or AF ablation * Exclusion Criteria : * No AF history * pregnant women * patient who didn't signed consent Group 1c * Inclusion Criteria : * AF/AT history * Stroke history * Exclusion Criteria : * No Stroke history * patient who didn't signed consent Group 2 * Inclusion Criteria : * patient over 80 * ECG: sinusal rhythm * TTE : no left atrial dilatation * Exclusion Criteria : * atrial fibrillation history * TTE : Left atria \>25cm², \> 34m/m2), FEVG \< 50% * ECG : QRS \> 90 ms * cardiac pathologies (excepted hypertension and valvulopathies) * History of stroke and transient ischemic attack * patient who didn't signed consent Group 3 * Inclusion Criteria : * cryptogenic stroke or transient ischemic attack history before 50 yo * No AF history * Exclusion Criteria : * AF history * stroke or transient ischemic attack over 50 yo * patient who didn't signed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03611816 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03611816 currently recruiting?
Yes, NCT03611816 is actively recruiting participants. Contact the research team at philippe.chevalier@chu-lyon.fr for enrollment information.
Where is the NCT03611816 trial being conducted?
This trial is being conducted at Bourg-en-Bresse, France, Bron, France, Bron, France, Pierre-Bénite, France and 1 additional location.
Who is sponsoring the NCT03611816 clinical trial?
NCT03611816 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.